NHD Global
Mitochondrial research · Elamipretide / SS-31
Scientific Product Dossier
SS-31, also called elamipretide, is a small peptide studied for its interaction with cardiolipin, a lipid in the inner mitochondrial membrane. That membrane helps cells make usable energy. Research findings depend on the disease model, preparation and measured endpoint. Catalog SS-31 and a regulated finished drug are different products. The sections below explain the mitochondrial research and show the catalog information to check before placing a research enquiry.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
The 12-patient randomized portion did not show superiority on 6-minute walk distance or the Barth syndrome fatigue score.
All participants were male; one US site; extremely small rare-disease dataset.
Read the primary studyFDA based accelerated approval on knee-extensor strength observed during longer open-label follow-up and required a post-approval randomized trial.
Approved indication: Barth syndrome in patients weighing at least 30 kg.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 50 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
U.S. FDA. Approval date September 19, 2025; SPIBA-201 population and endpoint record.
View primary recordReid Thompson W, et al. Genetics in Medicine. 2021. PMID 33077895.
View primary recordThird-party publications selected for direct relevance.
U.S. FDA. Approval date September 19, 2025; SPIBA-201 population and endpoint record.
Reid Thompson W, et al. Genetics in Medicine. 2021. PMID 33077895.
Concise answers for researchers comparing identity, evidence and catalog variants.
In Barth syndrome, a 12-patient randomized trial did not meet its two main goals: walking distance and a fatigue symptom score. During longer open-label follow-up, participants showed improvements in walking distance, fatigue score, knee-extensor strength and some heart measures. The FDA cited knee-extensor strength from that follow-up when granting accelerated approval to Forzinity, and required a confirmatory randomized trial. These results apply to the studied clinical product and population, not to catalog SS-31.
The FDA accelerated approval applies only to Forzinity, a finished drug, for a defined condition and patient weight. Approval decisions are tied to that application, formulation and clinical dataset. Catalog SS-31 is a research compound supplied for laboratory and development use, not the approved medicine. Findings from the Forzinity clinical program do not automatically apply to catalog material, other salt forms, blends, routes or doses. Catalog and clinical products are distinct categories when reading published evidence.
SS-31 and elamipretide refer to the peptide research lineage; Forzinity is a specific FDA-approved finished drug. A catalog SS-31 lot is not automatically that drug.
The 12-patient randomized crossover portion did not meet its 6-minute-walk or fatigue primary endpoints.
Family-level identifiers organize the catalog. Confirm the supplied form, identity and release criteria using the applicable product specification and ask which lot records are available.
Tell us which records your project requires. Availability and scope must be confirmed for the selected material. Published papers are not batch certificates, and this page does not confirm that a lot-specific COA is available.
Request the storage conditions for the exact supplied form and selected variant. A temperature stated for another supplier or a clinical drug preparation is not a verified storage specification for NHD catalog material.
No. A mechanism explains a possible biological pathway. Demonstrating an effect requires a defined experiment and endpoint. Findings in a specific disease study do not establish a general benefit for catalog material.
Send the exact product name, selected catalog variant, required quantity, destination and documents needed for the project. Specify whether the amount refers to powder mass or measured peptide content. Availability, price, lead time and document scope require confirmation.
No. A paper describes the material and methods used in that study. It does not establish the identity, purity or content of a different supplied lot. Ask which records actually apply to the requested material; do not assume a COA is available.
Knowledge center
Owned educational content connected to this family.
Elamipretide now has an FDA-approved finished product for a narrow Barth syndrome indication, but the approval rests on an unusual rare-disease dataset. The randomized…
Updated October 1, 2026
SS-31 and elamipretide are names used around the same mitochondrial-targeted peptide, but Forzinity is a specific FDA-approved finished drug with an approved application, formulation,…
Updated October 1, 2026
SS-31 is studied for its interaction with a lipid called cardiolipin in the inner mitochondrial membrane. This guide explains that relationship in plain language,…
Updated October 9, 2026
Separate the amount of cellular machinery from how well it works.
Updated October 11, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: 2S10 · 10 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
